Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297989 | 0.94 | CNR2 (0.35) | CNR2TRPV4TDP1CNR1TLR7 | |
| SCHEMBL476601 | 0.88 | CNR2 (0.38) | CNR2TRPV4TDP1CNR1TLR7 | |
| SCHEMBL476630 | 0.86 | TRPV4 (0.34) | CNR2TRPV4TDP1TLR7 | |
| SCHEMBL476609 | 0.85 | CNR2 (0.56) | CNR2TRPV4TDP1CNR1 | |
| SCHEMBL476631 | 0.83 | CNR2 (0.52) | CNR2TRPV4TDP1CNR1 | |
| SCHEMBL476586 | 0.83 | CNR2 (0.48) | CNR2CNR1PER2CRY1CRY2 | |
| SCHEMBL476660 | 0.82 | CNR2 (0.52) | CNR2TRPV4TDP1CNR1 | |
| SCHEMBL476623 | 0.82 | CNR2 (0.52) | CNR2TRPV4TDP1CNR1 | |
| SCHEMBL476585 | 0.82 | CNR2 (0.46) | CNR2TRPV4TDP1CNR1 | |
| SCHEMBL476687 | 0.81 | CNR2 (0.54) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951225-B1 | 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-02-01 | — | — | EP | claimed |
| US-20080275102-A1 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-06 | — | — | US | claimed |
| EP-1951225-B1 | 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-02-01 | — | — | EP | disclosed |
| US-7741363-B2 | 3-Acylindole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-06-22 | — | — | US | disclosed |
| US-20080275102-A1 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275102-A1 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | F12, ECI1, NQO2 | CNR2 31/4885TRPV4 4134/4885TDP1 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.